An acneiform eruption due to erlotinib: Prognostic implications and management [2]

Journal of the American Academy of Dermatology

Volumn 54, Issue 2, 2006, Pages 358-360

  Journagan, Susan ^a   Obadiah, Joseph ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ERYTHROMYCIN; MINOCYCLINE; RETINOIC ACID;

ACNE; ADULT; CASE REPORT; ERYTHEMA; FEMALE; HUMAN; KERATINOCYTE; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; SURVIVAL; TREATMENT OUTCOME; TUMOR GROWTH; XEROSIS;

EID: 31344454556     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.08.033     Document Type: Article

References (5)

1. E. Raymond, S. Faivre, and J.P. Armand Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drug 60 2000 15 23
2. R. Perez-Soler Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 17 2003 23 28
3. R. Herbst, P. LoRusso, M. Purdom, and D. Ward Dermatologic side effects associated with gefitinib therapy: clinical experience and management Clin Lung Cancer 4 2003 366 369
4. R. Herbst, and A. Sandler Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer Clin Lung Cancer 6 Suppl 2004 S7 S19
5. M. Lee, C. Seo, S. Kim, H. Yang, H. Lee, and J. Choi Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (zd1839), an inhibitor of epidermal growth factor Acta Derm Venereol 84 2004 23 26